Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05062096 | Characterization of NK Cells Under First Line Advanced Therapy Either as Curative Therapy for Metastatic Melanoma or as Adjuvant Therapy for High-risk of Recurrence(NAKIMEL) | unknown | N/A | 220 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Oct 4, 2022 | clinicaltrials |
| NCT04913025 | REduced Frequency ImmuNE Checkpoint Inhibition in Cancers(REFINE) | unknown | Phase 2 | 160 | University College, LondonOTHER |
| 1 |
| Sep 21, 2022 |
| clinicaltrials |
| NCT05510466 | Triple BRAFinh/MEKinh /antiPD1 Combined Therapy in Patients With BRAF Mutated Melanoma With Central Nervous System Metastasis | unknown | — | 18 | University Hospital, MontpellierOTHER | 1 | Aug 22, 2022 | clinicaltrials |
| NCT03934827 | MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour(MICROBIOME) | unknown | Phase 1 | 120 | Imperial College LondonOTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT05467137 | Sentinel Lymph Node Detection in Patients With Stage Ib-III Melanoma Using MSOT and ICG(MelanooMSOT) | unknown | Phase 4 | 10 | University Medical Center GroningenOTHER | 0 | Jul 20, 2022 | clinicaltrials |
| NCT05445752 | Conservative Nodal Surgery (Node-picking) of Patients With Stage III Melanoma With Low-burden of Nodal Disease (MELCONSURG MULTICENTRE COHORT) | unknown | — | 68 | Hospital Universitario Virgen MacarenaOTHER | 1 | Jul 6, 2022 | clinicaltrials |
| NCT05426317 | Exploratory Interventional Study of Prognostic Serum Biomarkers of Cancer Progression(Onco-PDL1s/B2M) | unknown | N/A | 100 | University Hospital, Clermont-FerrandOTHER | 1 | Jun 22, 2022 | clinicaltrials |
| NCT05402059 | Clinical Outcomes and Biomarkers in Patients With Stage 0-IV Melanoma in Real Clinical Practice(ISABELLA) | unknown | — | 1,570 | MelanomaPRO, RussiaOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT04353050 | Atypical MOLes and Melanoma Early Detection Study (MoleMed)(MoleMed) | unknown | N/A | 350 | Russian Academy of Medical SciencesOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT05402046 | Clinical vAlidation of a MobilE appLication ("ProRodinki") in the Assessment of the maLignant skIn neoplAsms(CAMELLIA) | unknown | N/A | 605 | MelanomaPRO, RussiaOTHER | 1 | Jun 2, 2022 | clinicaltrials |
| NCT05171374 | pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE(RATIONALE) | unknown | — | 500 | MelanomaPRO, RussiaOTHER | 1 | Jun 1, 2022 | clinicaltrials |
| NCT03374839 | Combined Therapy of Nivolumab and Adoptive T Cell Therapy in Metastatic Melanoma Patients(Nivo-TIL) | unknown | Phase 1 / Phase 2 | 11 | Nantes University HospitalOTHER | 1 | May 6, 2022 | clinicaltrials |
| NCT03385486 | Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors | unknown | Phase 1 | 72 | Taiga Biotechnologies, Inc.INDUSTRY | 1 | May 3, 2022 | clinicaltrials |
| NCT05114603 | A Phase II Clinical Trial to Evaluate HLX208 in Advanced Melanoma Patients With BRAF V600 Mutation | unknown | Phase 2 | 30 | Shanghai Henlius BiotechINDUSTRY | 1 | May 3, 2022 | clinicaltrials |
| NCT05340543 | Ex-vivo Examination of Excisions of Skin Tumors by Confocal Optical Coherence Tomography (LC-OCT) With Integrated Dermoscopy and Comparison With Histology (DERMOCTAV)(DERMOCTAV) | unknown | — | 150 | GCS Ramsay Santé pour l'Enseignement et la RechercheOTHER | 1 | Apr 22, 2022 | clinicaltrials |
| NCT02437279 | Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients(OpACIN) | unknown | Phase 1 | 20 | The Netherlands Cancer InstituteOTHER | 1 | Apr 15, 2022 | clinicaltrials |
| NCT02076646 | A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma | unknown | Phase 1 / Phase 2 | 96 | Philogen S.p.A.INDUSTRY | 2 | Apr 14, 2022 | clinicaltrials |
| NCT03161756 | Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma(CHARLI) | unknown | Phase 1 / Phase 2 | 72 | Melanoma and Skin Cancer Trials LimitedOTHER | 1 | Apr 7, 2022 | clinicaltrials |
| NCT02784366 | GI Complications in Cancer Immunotherapy Patients | unknown | — | 100 | Massachusetts General HospitalOTHER | 1 | Apr 5, 2022 | clinicaltrials |
| NCT02637531 | A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 | unknown | Phase 1 | 219 | Infinity Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 4, 2022 | clinicaltrials |
| NCT05119829 | Melanoma: Genomic Profiles, Molecular Markers and Therapeutic Implications | unknown | — | 80 | Hellenic Cooperative Oncology GroupOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT02994498 | Safety and Efficacy of DCB-BO1301 in Advanced Melanoma | unknown | Phase 1 / Phase 2 | 33 | Chung Mei Biopharma Co., LtdINDUSTRY | 0 | Mar 18, 2022 | clinicaltrials |
| NCT05274438 | Imatinib and Toripalimab in Patients With Locally Advanced/Metastatic Melanoma Harbored With CKIT Mut | unknown | Phase 2 | 37 | Peking University Cancer Hospital & InstituteOTHER | 1 | Mar 10, 2022 | clinicaltrials |
| NCT05235607 | Personalized Immune Cell Therapy Targeting Neoantigen of Malignant Solid Tumors | unknown | Phase 1 | 60 | Sichuan UniversityOTHER | 1 | Feb 11, 2022 | clinicaltrials |
| NCT05180851 | Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical Study(YSCH-01) | unknown | Early Phase 1 | 28 | Shanghai Fengxian District Central HospitalOTHER | 1 | Feb 1, 2022 | clinicaltrials |
| NCT04180995 | Toripalimab in Combination With Axitinib in Patients With Localized Mucosal Melanoma | unknown | Phase 2 | 30 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jan 31, 2022 | clinicaltrials |
| NCT04462965 | Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma Phase II Study | unknown | Phase 2 | 294 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jan 25, 2022 | clinicaltrials |
| NCT05190185 | A Clinical Trial of TAA06 Injection in Advanced Solid Tumors | unknown | Phase 1 | 18 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Jan 13, 2022 | clinicaltrials |
| NCT03715985 | Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac)(NeoPepVac) | unknown | Phase 1 / Phase 2 | 12 | Herlev HospitalOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT05179174 | The Role of Genetic Mutations and of Circulating mRNAs in Uveal Melanoma | unknown | — | 102 | University of CataniaOTHER | 2 | Jan 5, 2022 | clinicaltrials |
| NCT04025424 | Genetic Predictors of Efficiency and Safety of ICIs in Patients With Different Malignancies (ICIPRESIST-0519)(ICIPRESIST19) | unknown | — | 350 | Russian Academy of Medical SciencesOTHER | 1 | Dec 28, 2021 | clinicaltrials |
| NCT05103891 | Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations | unknown | Phase 1 | 14 | Pierre Fabre MedicamentINDUSTRY | 1 | Dec 1, 2021 | clinicaltrials |
| NCT05120024 | Multicenter Study of Safety and Efficacy of Prolgolimab in Patients With Advanced Melanoma in Routine Clinical Practice(FORA) | unknown | — | 350 | MelanomaPRO, RussiaOTHER | 1 | Nov 15, 2021 | clinicaltrials |
| NCT05117138 | Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors | unknown | Phase 1 / Phase 2 | 39 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Nov 11, 2021 | clinicaltrials |
| NCT03291002 | Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC | unknown | Phase 1 | 98 | CureVacINDUSTRY | 5 | Nov 4, 2021 | clinicaltrials |
| NCT05104801 | Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma | unknown | Phase 2 | 37 | Peking University Cancer Hospital & InstituteOTHER | 1 | Nov 4, 2021 | clinicaltrials |
| NCT00553618 | Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients(DTIC) | unknown | Phase 2 | 160 | University of LouisvilleOTHER | 1 | Oct 29, 2021 | clinicaltrials |
| NCT05097378 | Perioperative Encobini in BRAFV600 Mutant Stage III (B/C/D) or Oligometastatic Stage IV Melanoma(PREMIUM) | unknown | Phase 2 | 45 | CCTU- Cancer ThemeOTHER | 1 | Oct 28, 2021 | clinicaltrials |
| NCT03925350 | Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation | unknown | Phase 2 | 41 | California Pacific Medical Center Research InstituteOTHER | 1 | Oct 22, 2021 | clinicaltrials |
| NCT05089188 | PRAME Immunohistochemistry as an Adjunct for Evaluating Ambiguous Melanocytic Proliferation(ANTIPRAME) | unknown | — | 55 | University Hospital, Strasbourg, FranceOTHER | 1 | Oct 22, 2021 | clinicaltrials |
| NCT05070221 | Study of Oncolytic Virus in Combination With HX-008 and Axitinib in Melanoma Patients With Liver Metastasis | unknown | Phase 1 | 30 | Peking University Cancer Hospital & InstituteOTHER | 0 | Oct 7, 2021 | clinicaltrials |
| NCT05068453 | Study of Oncolytic Virus in Combination With HX-008 and Radiotherapy in Melanoma Patients With Liver Metastasis | unknown | Phase 1 | 15 | Peking University Cancer Hospital & InstituteOTHER | 0 | Oct 5, 2021 | clinicaltrials |
| NCT05047276 | Phase I/II Study of AloCelyvir in Patients With Metastatic Uveal Melanoma(PULSE-UM) | unknown | Phase 1 / Phase 2 | 16 | José María Piulats RodríguezOTHER | 1 | Sep 17, 2021 | clinicaltrials |
| NCT05009446 | Single Arm Study of Induction Chemoradiotherapy Combined With Surgery in the Treatment of Locally Advanced SNMM(SNMM) | unknown | Early Phase 1 | 28 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Aug 17, 2021 | clinicaltrials |
| NCT04521075 | A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC | unknown | Phase 1 / Phase 2 | 42 | Ella Therapeutics LtdINDUSTRY | 1 | Aug 16, 2021 | clinicaltrials |
| NCT04979585 | Camrelizumab Plus Amlotinib and Chemotherapy in the First-line Treatment of Melanoma | unknown | Phase 2 | 66 | Di WuOTHER | 1 | Aug 3, 2021 | clinicaltrials |
| NCT04177056 | Stereotactic Body Radiotherapy for Osseous Low Alpha-Beta Resistant Metastases for Pain Relief(SOLAR-P) | unknown | N/A | 40 | Hamilton Health Sciences CorporationOTHER | 1 | Aug 2, 2021 | clinicaltrials |
| NCT04871334 | Safety, Tolerability and Pharmacokinetics of TWP-101 in Patients With Advanced Melanoma and Urothelial Carcinoma | unknown | Phase 1 | 76 | Shandong TheraWisdom Biopharma Co., Ltd.INDUSTRY | 1 | Jul 23, 2021 | clinicaltrials |
| NCT04929353 | SYSTEMATIC SYMPTOM ASSESSMENT IN CANCER PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS(IRMA) | unknown | N/A | 280 | University Of PerugiaOTHER | 1 | Jun 18, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Oct 4, 2022source: clinicaltrials